The phrase "assessed data will" is correct and usable in written English.
It can be used when discussing the outcomes or implications of data that has been evaluated or analyzed.
Example: "The assessed data will provide insights into the effectiveness of our marketing strategies."
Alternatives: "evaluated data will" or "analyzed data will".
For assessing the appropriateness of analysis approaches, whether dropouts are independent of study outcome will be assessed ("data missing completely at random, MCAR", [ 63]).
We will assess data quality, scaling assumption, reliability and evidences for validity.
The psychometric study will assess data quality (including missing values), scaling assumptions (item variance, item-total correlation, multi-trait/multi-item correlation matrix), reliability (internal consistency and test-retest with calculation of Crombach's alpha and intraclass correlation index) and evidence for validity.
The coders assessing the data will be blind to group assignment; however, the person completing the blood sampling will not be blind as it is impossible to prevent them from knowing participant KMC condition (i.e., skin-to-skin or incubator care).
The first step in analysis will be to assess data quality to identify variables that are poorly or inconsistently recorded in medical records and/or women's accounts of labour and birth events.
Health care costs, patient and family costs, and production losses will be assessed, and relevant data will be collected thought retrospective cost diaries measured on a monthly basis during the entire study period.
These contradictions may be the result of differences in study design, study power or the populations assessed; therefore, additional data will be helpful to understand the role of CCR5 gene polymorphisms.
Although this approach can add to understanding of drug effects on the liver, it disregards the fact that predominant interest when assessing liver safety data will be on outliers in the data.
Furthermore, differences at each trial visit will be estimated along with the 95% confidence limits to assess excursions, and data will be evaluated as total responses during the study period using AUC (calculated by the trapezoidal rule) for the estimated and dose-corrected plasma liraglutide (secondary endpoints).
At three times during the study follow-up (at entry and at approximately 28 and 36 weeks) the nurse/nutritionist, trained in collecting anthropometric and diet data, will assess maternal nutritional status via anthropometry (weight, height, arm circumference, head circumference, skinfolds) (Table 1), as well as assessing the dietary intake (by twenty-four-hour recall).
